Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Tipapkinogene sovacivec |
Trade Name | |
Synonyms | MVA-HPV16E6/E7-IL2|R3484|RG3484|RO5217790|TG 4001|TG-4001|TG4001 |
Drug Descriptions |
Tipapkinogene sovacivec is a modified vaccinia virus Ankara (MVA)-based cancer vaccine, engineered to express the cytokine IL-2 and non-oncogenic versions of the human papilloma virus 16 (HPV16) proteins E6 and E7, which may lead to immune response and antitumor activity against HPV16 positive cancers (Annals of Oncology 30 Suppl 5 (2019): v494-v495; PMID: 30955915). |
DrugClasses | |
CAS Registry Number | 1052105-48-2 |
NCIT ID | C88326 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Avelumab + Tipapkinogene sovacivec | Avelumab Tipapkinogene sovacivec | 0 | 1 |
Tipapkinogene sovacivec | Tipapkinogene sovacivec | 0 | 0 |